A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer

INTRODUCTION: Fulvestrant shows dose-dependent biological activity. Greater estrogen-receptor (ER) blockade may feasibly be achieved by combining fulvestrant with anastrozole. This pre-surgical study compared fulvestrant plus anastrozole versus either agent alone in patients with ER-positive breast...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Robertson, John FR, Dixon, J Michael, Sibbering, D Mark, Jahan, Ali, Ellis, Ian O, Channon, Eddie, Hyman-Taylor, Pauline, Nicholson, Robert I, Gee, Julia MW
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2013
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3672778/
https://ncbi.nlm.nih.gov/pubmed/23497452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3393
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak